Key Facts

Invested since 2006
Based in Bavaria

About the company

KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare.

Exit since Feb. 2011. Purchaser: Evotec AG

Do you want to

know more about this company?

Zum Artikel

Dr. Caroline Fichtner Principal

Dr. Caroline FichtnerPrincipal

KINAXO in the news

Zum Artikel

Press

10. February 2011

Evotec acquires Kinaxo, Profitable Exit for Seed-Investor High-Tech Gründerfonds

More startups from Life Sciences